Sarepta Therapeutics (SRPT) Revenue (2010 - 2026)
Sarepta Therapeutics (SRPT) posted quarterly Revenue of $730.8 million for Q1 2026, up 448.1% year-over-year from $133.3 million in Q1 2025, and up 64.99% quarter-over-quarter from $442.9 million in Q4 2025.
Sarepta Therapeutics (SRPT) Revenue (2010 - 2026) Analysis & Trends
Sarepta Therapeutics' Revenue history runs 15 years deep, the most recent figure standing at $730.8 million for Q1 2026.
- In Q1 2026, Revenue rose 448.1% year-over-year to $730.8 million; the TTM figure through Mar 2026 stood at $2.2 billion (up 34.67% YoY), while the FY2025 annual figure was $1.9 billion, down 1.98% from the prior year.
- Revenue for Q1 2026 stood at $730.8 million, up from $442.9 million in the prior quarter.
- The five-year high for Revenue was $1.1 billion in Q4 2023, with the low at $133.3 million in Q1 2025.
- The 5-year median for Revenue is $399.4 million (2025), against an average of $446.8 million.
- The sharpest annual moves came in 2022 and 2025: Revenue surged 923.65% in 2022, then tumbled 67.75% in 2025.
- Sarepta Therapeutics' Revenue stood at $866.3 million in 2022, then advanced by 24.46% to $1.1 billion in 2023, then tumbled by 38.93% to $658.4 million in 2024, then plunged by 32.73% to $442.9 million in 2025, then surged by 64.99% to $730.8 million in 2026.
- Business Quant data shows SRPT's Revenue at $730.8 million in Q1 2026, $442.9 million in Q4 2025, and $399.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.33 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 4.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.56 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.71 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3,001.92 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 674.14 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.29 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 425.49 Mn |
| 10 | Sarepta Therapeutics | 1.91 Bn | 1.12 Bn | 251.87 Mn | 401.25 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 401.25 Mn |
| Mar 31, 2026 | 730.80 Mn |
| Dec 31, 2025 | 442.93 Mn |
| Sep 30, 2025 | 399.36 Mn |
| Jun 30, 2025 | 611.09 Mn |
| Mar 31, 2025 | 133.33 Mn |
| Dec 31, 2024 | 658.41 Mn |
| Sep 30, 2024 | 467.17 Mn |
| Jun 30, 2024 | 362.93 Mn |
| Mar 31, 2024 | 413.46 Mn |
| Dec 31, 2023 | 1.08 Bn |
| Sep 30, 2023 | 309.32 Mn |
| Jun 30, 2023 | 261.24 Mn |
| Mar 31, 2023 | 231.50 Mn |
| Dec 31, 2022 | 866.26 Mn |
| Sep 30, 2022 | 230.27 Mn |
| Jun 30, 2022 | 211.24 Mn |
| Mar 31, 2022 | 188.80 Mn |
| Dec 31, 2021 | 178.73 Mn |
| Sep 30, 2021 | 22.50 Mn |